I am a board certified hematologist specializing in bone marrow transplantation for leukemia, myelodysplastic syndromes, lymphoma, and other bone marrow disorders. I work in a collaborative fashion with other members of our team to provide comprehensive cancer care at Memorial Sloan Kettering Cancer Center. My research focuses on the role of Natural Killer (NK) cells in outcomes after transplantation. NK cells are white blood cells that have anti-tumor and anti-infection properties. My goal is to improve the transplantation process for patients via understanding and optimizing NK cell behavior. My clinical interests also include improving transplantation methods for patients without a matched sibling donor.
- Clinical Expertise: Autologous and allogeneic bone marrow transplantation; alternative donor transplantation
- Languages Spoken: English
- Education: Eastern Virginia Medical School
- Residencies: Wake Forest University Medical Center (North Carolina)
- Fellowships: National Cancer Institute (Maryland); National Heart, Lung and Blood Institute (Maryland)
- Board Certifications: Internal Medicine; Hematology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Brian Shaffer
- A Feasibility Study of Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells from Partially Matched Donors to Treat Acute Myelogenous Leukemia in Elderly Patients
- A Study Assessing Stem Cell Transplantation from a Half-Matched Related Donor, Using KIR Genes as well as Other Factors to Determine the Best Donor
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more